EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Characteristics of Arginase 1 Deficiency: Natural History Insights From International Clinical Trials

Mattias Rudebeck, Nancy Braverman, Richard Chang, Gregory M Enns, Arunabha Ghosh, Magali Gorce, Daniela Karall iD, Reena Sharma, Emily Shelkowitz, Roberto Zori, Markey McNutt iD

Journal of Inherited Metabolic Disease · 2026-03 · 49 (2)

DOI: 10.1002/jimd.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 06.02.2026. Verfasst von Mattias Rudebeck und 10 weiteren Autor:innen. Beteiligte Einrichtung: Immedica Pharma AB, Stockholm, Sweden. Hauptthemen laut MEDLINE: Arginase, Hyperargininemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aeglea BioTherapeutics Inc, Immedica Pharma AB, Immedica Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arginase 1 deficiency (ARG1‐D) is an ultra‐rare inherited metabolic disorder of the urea cycle, caused by partial or complete loss of arginase 1 function, characterised by hyperargininaemia and a distinct, progressive neurological phenotype. The clinical development programme of pegzilarginase, a recombinant human ARG1 enzyme therapy, provides an opportunity to study the largest ARG1‐D cohort to date. The analysis included 48 paediatric and adult subjects (≥ 2 years) enrolled in the pegzilarginase trials. Baseline data collected before treatment included demographics, genotypes, red blood cell arginase activity, biochemical measures, age of symptom onset, neuromotor and neurological characteristics, growth indicators, quality of life, and use of treatments and assistive devices. The mean (SD) age of onset was 2.2 (3.6) years, which preceded diagnosis at 3.7 (5.0) years. Clinical features included motor impairment (48/48, 100%), spasticity (33/48, 69%), cognitive deficits (31/48, 65%), intellectual disability (23/36, 64%), speech and language deficits (26/48, 54%), and seizures (18/48, 38%), with symptom‐onset data consistent with a progressive phenotype. Median GMFCS Level II indicated moderate mobility limitation; two‐thirds scored < 69 on FSIQ, and mean PedsQL total proxy scores were around 20% lower than typically developing peers. All subjects followed a protein‐restricted diet, and 90% used ammonia scavengers. ARG1‐D presents with a heterogeneous array of progressive and debilitating neurologic symptoms. These findings reflect the progressive impact of the disease and offer insights into its burden and natural history based on a large cohort, assessed using standardised neuromotor, cognitive, and quality‐of‐life instruments across international sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArginaseHyperargininemiaHumansChildChild, PreschoolFemaleMaleAdolescentAdultQuality of LifePhenotypeYoung AdultEnzyme Replacement TherapyAge of Onset

Stichwörter der Autor:innen

ARG1‐Darginase 1disease characteristicsnatural historyurea cycle disorders

Substanzen

ArginaseARG1 protein, human

Autor:innen und Institutionen

  • Immedica Pharma AB, Stockholm, Sweden.
  • Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
  • Rady Children's Health, Orange County, Orange, California, USA.
  • Stanford University School of Medicine and Lucille Packard Children's Hospital, Stanford, California, USA.
  • Willink Biochemical Genetics Unit, Manchester University Foundation Trust, Manchester, UK.
  • School of Biological Sciences, University of Manchester, Manchester, UK.

ORCID-Profile: Daniela Karall, Markey McNutt

Förderung

  • Aeglea BioTherapeutics Inc
  • Immedica Pharma AB
  • Immedica Pharma

Zitieren

APA

Rudebeck, M., Braverman, N., Chang, R., Enns, G. M., Ghosh, A., Gorce, M., Karall, D., Sharma, R., Shelkowitz, E., Zori, R., & McNutt, M. (2026). Clinical Characteristics of Arginase 1 Deficiency: Natural History Insights From International Clinical Trials. Journal of Inherited Metabolic Disease, 49(2). https://doi.org/10.1002/jimd.70156

Vancouver

Rudebeck M, Braverman N, Chang R, Enns GM, Ghosh A, Gorce M, et al. Clinical Characteristics of Arginase 1 Deficiency: Natural History Insights From International Clinical Trials. Journal of Inherited Metabolic Disease. 2026;49(2). doi:10.1002/jimd.70156

BibTeX
@article{Rudebeck2026,
  author = {Rudebeck, Mattias and Braverman, Nancy and Chang, Richard and Enns, Gregory M and Ghosh, Arunabha and Gorce, Magali and Karall, Daniela and Sharma, Reena and Shelkowitz, Emily and Zori, Roberto and McNutt, Markey},
  title = {Clinical Characteristics of Arginase 1 Deficiency: Natural History Insights From International Clinical Trials},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {2},
  doi = {10.1002/jimd.70156}
}
Kostenlos starten →